Download pdf
Prevalence of antibiotic resistance in Clostridium difficile: A meta-analysis
- 1 Wuhan University
- 2 Sun Yat-Sen University
- 3 Guangzhou Medical University
* Author to whom correspondence should be addressed.
Abstract
In recent years, the resistance of Clostridium difficile to various common mainstream antibiotics cannot be ignored, the incidence of CDI in many areas is also increasing year by year, posing a great threat to public safety. Literature collection was carried out on 6 open databases, and high-quality literature data conforming to classification criteria were screened and extracted. The WPR and WPF of each antibacterial drug were calculated using the random effects model. Subgroup analysis was used to investigate the influence of regional and experimental methods. Results: A total of 40 studies were included. The WPR of vancomycin was 0.0372, 95%CI: [0.0148; 0.0671], I²: 93.7%, WPF was 0.2195, I²: 94.0%. The WPR of fidaxomicin was 0.0051, 95%CI: [0.0000; 0.0205], I²: 82.7%, WPF was 0.1757, I²: 93.6%. The WPR of metronidazole was 0.0318, 95%CI: [0.0056; 0.0727], I²: 91.6%. Among the three antibiotics, the highest resistance of C. difficile to metronidazole were mainly distributed in the Middle East and Africa. The conclusion seems to indicate that C. difficile is most sensitive to Fidaxomicin, and the clinical cure rate is better than vancomycin. However, the clinical cure failure rate increased significantly from 2007 to 2019, while the drug resistance rate did not change significantly, suggesting that other factors besides drug resistance may affect the therapeutic effect of fidaxomicin on CDI. There was no significant difference in the results of AGAR dilution and e test, the main methods for drug susceptibility testing.
Keywords
Clostridium difficile, antimicrobial resistance, meta-analysis.
[1]. Modaber I 1975 Clostridium difficile. J. Acta Med Iran, 18(3-4), 111-128.
[2]. Hall I C and O’toole E 1935 Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. J. American journal of diseases of children, 49(2), 390-402.
[3]. Bartlett J G, Chang T W, Gurwith M, et al. 1978 Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. J. The New England journal of medicine, 298(10), 531-534.
[4]. Sandhu B K, Mcbride S M 2018 Clostridioides difficile. J. Trends in microbiology, 26(12), 1049-1050.
[5]. Ramirez J, Guarner F, Bustos Fernandez L, et al. 2020 Antibiotics as Major Disruptors of Gut Microbiota. J. Frontiers in cellular and infection microbiology, 10, 572912.
[6]. Reigadas E, Van Prehn J, Falcone M, et al. 2021 How to: prophylactic interventions for prevention of Clostridioides difficile infection. J. Clin Microbiol Infect, 27(12), 1777-1783.
[7]. Feuerstadt P, Louie T J, Lashner B, et al. 2022 SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. J. The New England journal of medicine, 386(3), 220-9.
[8]. Carlson T and Gonzales-Luna A J 2020 Antibiotic treatment pipeline for Clostridioides difficile infection (CDI): A wide array of narrow-spectrum agents. J. Current infectious disease reports, 22, 1-11.
[9]. Stogios P J and Savchenko A 2020 Molecular mechanisms of vancomycin resistance. J. Protein science: a publication of the Protein Society, 29(3), 654-669.
[10]. Oprita R, Bratu M, Oprita B, et al. 2016 Fecal transplantation - the new, inexpensive, safe, and rapidly effective approach in the treatment of gastrointestinal tract diseases. J. Journal of medicine and life, 9(2), 160-162.
[11]. Spigaglia P, Mastrantonio P and Barbanti F 2018 Antibiotic Resistances of Clostridium difficile. J. Advances in experimental medicine and biology, 1050, 137-159.
[12]. Lessa F C, Mu Y, Bamberg W M, et al. 2015 Burden of Clostridium difficile infection in the United States. J. The New England journal of medicine, 372(24), 2369–2370.
[13]. Kuijper E, Coignard B, Tüll P, et al. 2006 Emergence of Clostridium difficile‐associated disease in North America and Europe. J. Clin Microbiol Infect, 12, 2-18.
[14]. Dai J, Gong J and Guo R 2022 Real-world comparison of fidaxomicin versus vancomycin or metronidazole in the treatment of Clostridium difficile infection: a systematic review and meta-analysis. J. European Journal of Clinical Pharmacology, 78(11), 1727-1737.
Cite this article
Guo,T.;Jiang,Z.;Yu,Q. (2023). Prevalence of antibiotic resistance in Clostridium difficile: A meta-analysis. Theoretical and Natural Science,27,202-210.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 2nd International Conference on Modern Medicine and Global Health
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).